Mixing COVID-19 Vaccine Study Adds Two Other Vaccines

In COVID-19, Latest News by Precision Vaccinations

Researchers conducting the Com-Cov clinical study investigating alternating doses of the AstraZeneca and the Pfizer-BioNTech COVID-19 vaccines announced that the program now includes the Moderna and Novavax vaccines.
Study volunteers will receive either the AstraZeneca or Pfizer vaccine, will be randomly allocated to receive either the same vaccine for their second dose or a dose of the COVID-19 vaccines produced by Moderna or Novavax.
The six new ‘arms’ of the Com-Cov trial will each recruit 175 candidates, adding a further 1,050 recruits into this innovative program. 

Read More